share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  09/06 17:00
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.
Recursion Pharmaceuticals首席執行官Christopher Gibson於2024年9月4日和5日完成了對公司A類普通股的40,000股股份的銷售。這些交易的執行價格介於6.04美元至6.14美元每股,總市值爲243,600美元。銷售完成後,Gibson直接持有Recursion Pharmaceuticals的762,656股股份。
Recursion Pharmaceuticals首席執行官Christopher Gibson於2024年9月4日和5日完成了對公司A類普通股的40,000股股份的銷售。這些交易的執行價格介於6.04美元至6.14美元每股,總市值爲243,600美元。銷售完成後,Gibson直接持有Recursion Pharmaceuticals的762,656股股份。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息